Market Energy – Drug Diversion Monitoring Comments

Decision Insights

Drug Diversion Monitoring 2021

04 January 22 | Jackson Tate and Jennifer Hickenlooper

In the last 12 months, KLAS has interviewed 41 healthcare organizations that have recently purchased a drug diversion monitoring solution or are in the process of doing so. This represents a sharp increase in market activity. Several factors are fueling the growth, including greater awareness of the opioid crisis as well as a greater need during the COVID-19 pandemic for visibility and automation when it comes to managing medication inventories. Additionally, organizations are considering several newer technology options purported to offer more intuitive workflows and more complete investigational tools. This report examines recent and upcoming drug diversion monitoring purchase decisions to determine which vendors are generating the highest interest.

Decision Insights™ Drug Diversion Monitoring Commentary

Interview Timeframe

Decision Insights™ Drug Diversion Monitoring Commentary

Interview Timeframe

Contact KLAS

Tell us about your organization

How can we help you?